TargetBeta
BCL2
BCL2 apoptosis regulator · also Bcl-2, PPP1R50 · Protein phosphatase 1 regulatory subunits
7 programs in company-led studies act on BCL2, from 4 companies: 1 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| venetoclaxrule | AbbVie | phase 4 | 8325 running | – | ChEMBL |
| Bcl-2 Inhibitor TQB3909 | Sino Biopharmaceutical | phase 3 | 85 running | – | the company's pipeline |
| lacutoclaxrule | Lupeng Pharmaceutical | phase 2 | 43 running | – | the studies' text |
| surzetoclax | AbbVie | phase 2 | 33 running | – | the company's pipeline |
| 400mg of TQB3909 tablets | Sino Biopharmaceutical | phase 2 | 10 running | – | the company's pipeline |
| surzetoclax | AbbVie | phase 1 | 22 running | – | the company's pipeline |
| FXS0683 | Fosun Pharma | phase 1 | 11 running | – | the company's pipeline |
Conditions their studies are in
- Leukemia, Lymphocytic, Chronic, B-Cell, 5 programs
- Lymphoma, Mantle-Cell, 3 programs
- Multiple Myeloma, 3 programs
- Leukemia, Myeloid, Acute, 2 programs
- Breast Neoplasms, 1 program
- Hematologic Neoplasms, 1 program
- Lymphoma, B-Cell, 1 program
- Lymphoma, Non-Hodgkin, 1 program
- Precursor Cell Lymphoblastic Leukemia-Lymphoma, 1 program
- Primary Myelofibrosis, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 2026venetoclax · AbbVie · phase 4 · NCT04895436
- Jul 2027surzetoclax · AbbVie · phase 2 · NCT06291220
- Jul 2027surzetoclax · AbbVie · phase 1 · NCT06291220
- Dec 31, 2027lacutoclax · Lupeng Pharmaceutical · phase 2 · NCT05641259
- Aug 7, 2028FXS0683 · Fosun Pharma · phase 1 · NCT07616089
- Dec 2030Bcl-2 Inhibitor TQB3909 · Sino Biopharmaceutical · phase 3 · NCT07753369
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.